Background Experimental and clinical evidence supports the role of inflammation in
atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

ContextHigh-density lipoprotein (HDL) cholesterol is an inverse predictor of coronary
atherosclerotic disease. Preliminary data have suggested that HDL infusions can induce …

Background The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises
the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we provide
comprehensive recommendations and practical tips for the pharmacologic management …

Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits
of targeting inflammation after myocardial infarction (MI). We aimed to determine whether …

The 2012 Canadian Cardiovascular Society Heart Failure (HF) Guidelines Update provides
management recommendations for acute and chronic HF. In 2006, the Canadian …

The 2011 Canadian Cardiovascular Society Heart Failure (HF) Guidelines Focused Update
reviews the recently published clinical trials that will potentially impact on management. Also …

Background In trials of patients with left ventricular dysfunction or heart failure, ACE inhibitor
use was unexpectedly associated with reduced myocardial infarction (MI). Using the Heart …

Background— Production of leukotrienes by 5-lipoxygenase (5-LO) has been linked to unstable
atherosclerotic plaques and cardiovascular events. VIA-2291 is a potent 5-LO inhibitor. …